{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:12:33Z","timestamp":1790896353785,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.pupt.2008.09.001","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T19:03:32Z","timestamp":1223492612000},"page":"855-859","source":"Crossref","is-referenced-by-count":33,"title":["Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial"],"prefix":"10.1016","volume":"21","author":[{"given":"Lennert","family":"Slobbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.A.","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2008.09.001_bib1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","article-title":"Therapeutic outcome in invasive aspergillosis","volume":"23","author":"Denning","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2008.09.001_bib2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"Denning","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2008.09.001_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2008.09.001_bib4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","article-title":"Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients","volume":"67","author":"Maschmeyer","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2008.09.001_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pupt.2008.09.001_bib6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/323900","article-title":"The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis","volume":"33","author":"Perfect","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"10.1016\/j.pupt.2008.09.001_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1086\/504490","article-title":"Invasive fungal pathogens: current epidemiological trends","volume":"43","author":"Pfaller","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2008.09.001_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2008.09.001_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2008.09.001_bib10","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","author":"Schwartz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pupt.2008.09.001_bib11","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2002-05-1356","article-title":"Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies","volume":"101","author":"Cornely","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pupt.2008.09.001_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2008.09.001_bib13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: randomized placebo controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2008.09.001_bib14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/jac\/34.6.1001","article-title":"Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis","volume":"34","author":"Allen","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2008.09.001_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.41.2.259","article-title":"Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis","volume":"41","author":"Cicogna","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2008.09.001_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/jam.1996.9.111","article-title":"Liposomal aerosols in the management of pulmonary infections","volume":"9","author":"Gilbert","year":"1996","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.pupt.2008.09.001_bib17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1021\/js9604218","article-title":"Disposition of aerosolized liposomal amphotericin B","volume":"86","author":"Lambros","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pupt.2008.09.001_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1211\/0022357001774417","article-title":"Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats","volume":"52","author":"Ruijgrok","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pupt.2008.09.001_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1086\/586740","article-title":"Aerosolized antifungal prophylaxis: the winds of change?","volume":"46","author":"Perfect","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2008.09.001_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","article-title":"Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients","volume":"77","author":"Drew","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.pupt.2008.09.001_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3062.2007.00209.x","article-title":"Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study","volume":"9","author":"Lowry","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.pupt.2008.09.001_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2008.09.001_bib23","first-page":"184","article-title":"Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study","volume":"52","author":"Van Dyke","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.pupt.2008.09.001_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2008.09.001_bib25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/thx.51.10.973","article-title":"Long-term performance of a hand held spirometer","volume":"51","author":"Dirksen","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2008.09.001_bib26","unstructured":"\u3008http:\/\/www.fda.gov\/cder\/cancer\/toxicityframe.htm\u3009 (last access: September 7, 2008)."},{"key":"10.1016\/j.pupt.2008.09.001_bib27","unstructured":"Ruiz I, Molina I, Gavalda J. Safety and tolerability of nebulized liposomal amphotericin-B in haematologic patients. In: Proceedings of the 45th interscience conference on antimicrobial agents and chemotherapy, 2005 [abstract M-977]."},{"key":"10.1016\/j.pupt.2008.09.001_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007890-200108150-00036","article-title":"Safety of aerosolized amphotericin B lipid complex in lung transplant recipients","volume":"72","author":"Palmer","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.pupt.2008.09.001_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.pupt.2008.09.001_bib30","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1378\/chest.123.6.1983","article-title":"The pulmonary effects of long-term exposure to aerosol pentamidine: a 5-year surveillance study in HIV-infected patients","volume":"123","author":"Obaji","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2008.09.001_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/AAC.34.1.29","article-title":"Pharmacokinetics of aerosol amphotericin B in rats","volume":"34","author":"Niki","year":"1990","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553908000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553908000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T13:54:40Z","timestamp":1557842080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553908000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1094553908000904"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2008.09.001","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}